Researchers found that a common blood pressure medication, known as dihydropyridine calcium-channel blockers (DCCBs), may increase the risk of serious kidney problems by 33% in people with type 2 diabetes. This surprising discovery raises concerns about the safety of DCCBs, particularly for those already taking kidney-protective medications. The findings were presented at the 63rd Congress of the European Renal Association and suggest that DCCBs, often used as second-line treatments for diabetic kidney disease, might not always be the best choice.

This matters for anyone managing type 2 diabetes and concerned about kidney health. Diabetic kidney disease is a leading cause of kidney failure, and keeping blood pressure under control is crucial for preventing further damage. The study analyzed data from over 31,000 adults with type 2 diabetes, revealing that those who took DCCBs alongside standard kidney-protective therapies faced a significantly higher risk of major kidney events, such as a drastic decline in kidney function or the need for dialysis.

While the research is based on observational data, meaning it can’t definitively prove that DCCBs cause kidney problems, the association is concerning enough to warrant further investigation. The study highlights the need for more rigorous trials to explore the safest blood pressure treatment options for those with diabetic kidney disease. As the use of DCCBs is widespread, any increased risk could impact a large number of patients.

For more details, check out the original post on Science Daily.